Original reporting and analysis on the stories shaping biotech.
Eli Lilly and Boehringer Ingelheim each slashed over €1 billion from their German investment plans in the same week, citing a sweeping healthcare reform bill. When two pharma giants retreat from Europe's largest economy simultaneously, it's not a coincidence; it's a continent-wide wake-up call.
Odyssey Therapeutics just pulled in $304 million from an upsized IPO and a same-day private placement, all on the strength of a single mid-stage drug. It's one of the cleanest biotech debuts in years, and it says a lot about where the 2026 IPO market is headed.
Travere Therapeutics just bet $1.1 billion on a BTK inhibitor it licensed from Everest Medicines, and the deal could reshape how immune-mediated kidney diseases are treated. The stock dropped 6% anyway. Here's what Wall Street is missing.
BMS unveiled Phase 3 data on a bispecific ADC that targets EGFR and HER3 instead of TROP2, posting striking survival results in triple-negative breast cancer. The data could reshape the competitive dynamics of the entire ADC landscape and put Gilead and AstraZeneca's TROP2 franchises on defense.
Eli Lilly just committed up to $1.9 billion to Ascidian Therapeutics for a technology that fixes genetic errors without ever touching DNA. The target: inherited kidney diseases that currently have almost no treatments. Here's why two pharma giants are now betting billions on the same platform.
Celcuity showed up to ASCO 2026 with one drug, one positive Phase 3 trial, and a vision to become a $10 billion company. With an FDA decision weeks away and a 960% stock surge behind it, the question isn't whether the ambition is real; it's whether a single molecule can carry it.
Cytokinetics spent 27 years and $2.1 billion before getting its first drug approved. Now its pivotal trial in non-obstructive HCM just hit both endpoints, opening a market its biggest rival already failed to crack.
Coinbase co-founder Brian Armstrong's anti-aging biotech just raised $435 million at a $3.1 billion valuation, and it hasn't treated a single human patient yet. The plan: reprogram old liver cells to act young again, starting clinical trials next year.
Roche's oral SERD giredestrant failed to beat the first-line breast cancer standard in a 992-patient phase 3 trial, and Wall Street is already repricing the drug's future. But two other positive trials mean giredestrant's story isn't over; it's just a very different story than Roche planned.
Intellia just delivered the first successful Phase 3 trial for an in vivo CRISPR therapy, cutting hereditary angioedema attacks by 87% with a single infusion. The results could reshape how we think about treating genetic diseases forever.
Legend Biotech just showed it can build CAR-T cells inside a patient's body with a single injection, no factory required. The early data are stunning, the implications are enormous, and the race to replace today's six-week manufacturing nightmare just got very real.
Telix Pharmaceuticals just presented early safety data for a Phase 3 challenger to Novartis's $2 billion blockbuster Pluvicto in prostate cancer. The oven is warming up, but the real test is still ahead.
Servier just paid $1.55 billion upfront (with another $1.1 billion in milestones) for an oral pill that could become the first approved treatment for Becker muscular dystrophy. The pivotal trial data drop later this year, and analysts are modeling $2.2 billion in peak sales.
For 24 years, no drug has been able to knock Gleevec off its throne as the go-to treatment for GIST. GSK just showed up at ASCO 2026 with early data on velzatinib that has oncologists using the words "paradigm shift" — but the phase 3 gauntlet is just beginning.
Abivax reported some of the best ulcerative colitis data ever seen, with 51% remission rates that blew away placebo. Then investors noticed the cancer cases in the safety tables, and the stock cratered 30-40% in a single day.
Fulcrum Therapeutics' sickle cell drug showed real promise, but the FDA shut it down over cancer fears tied to an entire drug class. The stock cratered 50%, the company's only clinical program vanished, and the implications stretch far beyond one biotech.
UCB swooped in with $2 billion in cash to snag Candid Therapeutics, killing the company's planned IPO in the process. The deal spotlights big pharma's growing obsession with T-cell engagers for autoimmune disease and signals that 2026's M&A frenzy is just getting started.
Revolution Medicines' daraxonrasib just doubled overall survival in metastatic pancreatic cancer, shattering a barrier that's stood for decades. Now the FDA has cleared an early access program before the drug is even approved, and Wall Street thinks this could be a $10 billion opportunity.
A first-in-class bispecific antibody just cut the risk of death by 34% in lung cancer, outperforming a modern immunotherapy combo. The catch? The entire trial was run in China, and Wall Street wanted more.
Eli Lilly just licensed a long-acting GLP-2 drug from South Korea's Hanmi Pharma in a deal worth up to $1.26 billion. The target: a rare gut disease where the only approved treatment demands a daily injection, and the promise of replacing it with one shot per month.
BioNTech is shutting down four manufacturing sites, cutting 22% of its workforce, and handing all COVID vaccine production to Pfizer. The reason? A massive, €17.4-billion-funded bet that its future lies in cancer, not pandemics.
Eli Lilly just committed up to $3 billion to partner with a Chinese drugmaker most Western investors have never heard of. The deal covers five undisclosed drug programs, and the secrecy is almost as interesting as the price tag.
Join thousands of biotech professionals who start their day with our free, daily briefing.